Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
GLOBETECH PUBLISHING
JIB

New Drug Combo Could Prevent Head and Neck Cancer in High-Risk Patients

By BiotechDaily International staff writers
Posted on 12 Mar 2013
Image: The arrows point to cancerous lymph nodes on both sides of the neck (Photo courtesy of the [US] National Cancer Institute).
Image: The arrows point to cancerous lymph nodes on both sides of the neck (Photo courtesy of the [US] National Cancer Institute).
A new combination of drugs has demonstrated potential in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck.

“Squamous cell carcinoma of the head and neck [SCCHN] is the most common type of head and neck cancer,” said Dong Moon Shin, MD, professor of hematology, medical oncology and otolaryngology at Emory University School of Medicine (Atlanta, GA, USA), and director of the Cancer Chemoprevention Program at Winship Cancer Institute at Emory University. “The survival rate for patients with SCCHN is very poor. An effective prevention approach is desperately needed, especially since we can identify patients who are at extremely high risk: those with advanced oral precancerous lesions.”

Based on earlier research suggesting a role for epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) in promoting SCCHN, Dr. Shin and colleagues believed combining an EGFR inhibitor and a COX-2 inhibitor could provide an effective chemopreventive approach. They found that the combination of the EGFR inhibitor erlotinib and the COX-2 inhibitor celecoxib was more effective for inhibiting the growth of human SCCHN cell lines compared with either drug alone. Moreover, treating mice with the drug combination prior to transplanting them with human SCCHN cells more effectively suppressed cancer cell growth than did pretreating the mice with either drug alone.

Dr. Shin and colleagues, based on these preclinical analyses, initiated a phase I chemoprevention trial. Eleven patients with advanced oral precancerous lesions were assigned to treatment with erlotinib and celecoxib. Tissue samples from the patients were taken and assessed pathologically at 3, 6, and 12 months after the start of therapy. Biopsies at baseline and follow-up were available for seven patients. The study’s findings, which included preclinical and clinical analyses, were published February 2013 in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Pathologic examination of the biopsies indicated that three of the seven patients had a complete pathologic response; that is, there was no longer evidence of the precancerous lesions in the follow-up biopsy sample. Among the other patients, two had a partial pathologic response and two had progressive disease. “Finding that this drug combination caused some advanced premalignant lesions to completely disappear was great news,” remarked Dr. Shin. “Advanced premalignant lesions rarely regress, so our data are proof-of-principle that a combination chemopreventive strategy with molecularly targeted agents is possible.”

Several patients dropped out of the trial because of severe adverse side effects, according to Dr. Shin. “Prevention is not achieved through short-term treatment,” he said. “So, we need to investigate the safety and toxicity of this combination further before planning a large-scale trial. We are also looking to combination therapies using less toxic or nontoxic agents, such as natural compounds.”

Related Links:

Emory University School of Medicine




comments powered by Disqus

Channels

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.